Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2002-03-27 | Ms. Parker received her B.A. and M.B.A. from the University of Washington. |
| 2003-03-27 | Ms. Parker received her B.A. and M.B.A. from the University of Washington. |
| 2004-03-24 | H. Stewart Parker (age 48) managed the formation of Targeted Genetics as a wholly owned subsidiary of Immunex Corporation and has served as president, chief executive officer and a director of Targeted Genetics since our inception in 1989. She served in various capacities at Immunex from August 1981 through December 1991, most recently as vice president, corporate development. Ms. Parker also served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products, from February 1991 to January 1993. Ms. Parker has served as chairman of the board of CellExSys, Inc., our majority-owned cell therapy subsidiary, since December 2000. She serves on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry, and as a director of several privately-held companies. Ms. Parker received her B.A. and M.B.A. from the University of Washington. |
| 2005-04-14 | Ms. Parker received her B.A. and M.B.A. from the University of Washington. |
| 2006-03-29 | Ms. Parker received her B.A. and M.B.A. from the University of Washington. |
| 2007-04-02 | Ms. Parker holds a B.A. and M.B.A. from the University of Washington and has served as president and CEO. |
| 2007-11-21 | H. Stewart Parker - President and Chief Executive Officer |
| 2008-03-28 | Ms. Parker holds a B.A. and an M.B.A. from the University of Washington. |
| 2019-10-22 | Ms. Parker received her B.A. and M.B.A. from the University of Washington. |
| 2020-03-06 | H. Stewart Parker (Director) |
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-28 | Ms. Parker's senior executive experience in AAV gene therapy and biotechnology drug development provides valuable operational, commercial assessment and management skills to the Board. |
| 2016-04-25 | Ms. Parker has over 30 years of experience in the biotechnology industry and served as CEO of gene therapy companies. |
| 2017-04-25 | Ms. Parker has over 30 years of experience in the biotechnology industry. She founded Targeted Genetics Corporation, a biopharmaceutical company formed to develop gene-based treatments. |
| 2018-04-24 | Ms. Parker received her B.A. and M.B.A. from the University of Washington. |
| 2019-04-25 | Ms. Parker received her B.A. and M.B.A. from the University of Washington. |
| 2020-04-02 | Ms. Parker received her B.A. and M.B.A. from the University of Washington. |
| 2021-04-02 | Ms. Parker founded Targeted Genetics Corporation, a biopharmaceutical company formed to develop gene-based treatments, and served as CEO and board member. |
| 2022-04-01 | Ms. Parker has over 40 years of experience in the biotechnology industry. She founded Targeted Genetics Corporation, a biopharmaceutical company formed to develop gene-based treatments. |
| 2023-04-17 | Ms. Parker received her B.A. and M.B.A. from the University of Washington. |
| 2024-04-19 | Ms. Parker has over 40 years of experience in the biotechnology industry. Prior to focusing on board service and consulting, she served as the Chief Executive Officer of The Infectious Disease Research Institute (IDRI), a not-for-profit global health research institute from 2011 to 2013. |
Data sourced from SEC filings. Last updated: 2025-10-12